News Image

Immatics Announces Full Year 2024 Financial Results and Business Update

Provided By GlobeNewswire

Last update: Mar 27, 2025

Houston, Texas and Tuebingen, Germany, March 27, 2025 Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2024.

Read more at globenewswire.com

IMMATICS NV

NASDAQ:IMTX (7/24/2025, 3:41:06 PM)

6.47

+0.02 (+0.31%)



Find more stocks in the Stock Screener

Follow ChartMill for more